524661 WELCURE

Welcure Drugs & Pharmaceuticals Share Price

 

Stock touched 52W low

 

Start SIP in WELCURE

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹1
  • Open Price₹0
  • Previous Close₹0
  • Volume6,825,987
  • 50 DMA₹0.50
  • 100 DMA₹0.61
  • 200 DMA₹0.70

Investment Returns

  • Over 1 Month -22%
  • Over 3 Month -46.58%
  • Over 6 Month -66.95%
  • Over 1 Year -59.38%

Smart Investing Starts Here Start SIP with Welcure Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Welcure Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 1.4
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 48
  • P/B Ratio
  • 0.4
  • Average True Range
  • 0.02
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.03
  • RSI
  • 33.77
  • MFI
  • 23.96

Welcure Drugs & Pharmaceuticals Financials

Welcure Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹0.39
-0.01 (-2.5%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹0.44
  • 50 Day
  • ₹0.50
  • 100 Day
  • ₹0.61
  • 200 Day
  • ₹0.70

Resistance and Support

0.4 Pivot Speed
  • R3 0.43
  • R2 0.42
  • R1 0.41
  • S1 0.39
  • S2 0.38
  • S3 0.37

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Welcure Drugs & Pharms. has an operating revenue of Rs. 395.59 Cr. on a trailing 12-month basis. An annual revenue growth of 29300% is outstanding, Pre-tax margin of 11% is healthy, ROE of 2% is fair but needs improvement. The company has a high debt to equity of 120%, which can be a reason to worry. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 1 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 96 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Welcure Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-12-05 Right Issue of Equity Shares
2025-11-27 To consider raisinf of funds Inter-alia, 1. To augment the financial resources of the Company via funds raising by way of issue of equity shares/convertible instruments/other securities through permissable modes. split from Rs. 10/- to Re. 1/-.
2025-11-13 Quarterly Results
2025-09-27 Others Inter-alia, 1. To take on record and deliberate upon the Letter of Intent (LOI) received from Telexcell Trade PTE LTD, Singapore, for a proposed acquisition of up to 25% equity stake (Revised) split from Rs. 10/- to Re. 1/-.
2025-09-02 A.G.M.
Date Purpose Remarks
2025-10-16 Split Rs.0.00 split from Rs. 10/- to Re. 1/-.
Date Purpose Remarks
2025-10-16 Bonus Re.0.00 issue of equity shares in the ratio of 1:10 of Re. 1/-.

Welcure Drugs & Pharmaceuticals F&O

Welcure Drugs & Pharmaceuticals Shareholding Pattern

0%
0%
0%
0%
0%
94.41%
5.59%

About Welcure Drugs & Pharmaceuticals

  • NSE Symbol
  • WELCURE
  • BSE Symbol
  • 524661
  • Managing Director
  • Mr. Chintan Didawala
  • ISIN
  • INE331C01025

Similar Stocks to Welcure Drugs & Pharmaceuticals

Welcure Drugs & Pharmaceuticals FAQs

Welcure Drugs & Pharmaceuticals share price is ₹0 As on 14 January, 2026 | 15:56

The Market Cap of Welcure Drugs & Pharmaceuticals is ₹48.2 Cr As on 14 January, 2026 | 15:56

The P/E ratio of Welcure Drugs & Pharmaceuticals is 1.4 As on 14 January, 2026 | 15:56

The PB ratio of Welcure Drugs & Pharmaceuticals is 0.4 As on 14 January, 2026 | 15:56

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23